Background
==========

Mesenchymal stem cells (MSCs) are morphologically fibroblast-like cells that are characterized by their ability to both self-renew and differentiate into tissues of mesodermal origin (osteoblasts, adipocytes, chondrocytes and myocytes) \[[@B1]\]. However, MSCs can also give rise to other cell types such as astrocytes and neurons \[[@B2],[@B3]\]. This indicates cellular pluripotency and suggests that MSCs are responsible for the normal turnover and maintenance of adult mesenchymal tissues \[[@B4]\].

Sheep is an ideal model for bone tissue engineering \[[@B5]\] and has been proposed as an animal model for a wide range of applications in biomedical research, such as for the studies of respiratory diseases \[[@B6]\], cardiomyopathies \[[@B7],[@B8]\], neurological disorders \[[@B9]\] and prion diseases \[[@B10],[@B11]\].

Although MSCs are generally obtained from the bone marrow \[[@B12]\], they can also be isolated from other sources such as adipose tissue, umbilical cord blood and foetal tissues \[[@B13],[@B14]\]. The isolation of MSCs from peripheral blood (PB-MSCs) has been reported for a variety of mammals including guinea pigs, rabbits, dogs, mice, rats, horses and humans \[[@B15]-[@B19]\]. Because blood harvesting is a less invasive procedure to obtain stem cells, this method would represent a significant advantage for patients and, therefore, would be an ideal candidate technique to obtain PB-MSCs for future clinical applications. Moreover, monitoring the presence and the proportional quantity of MSCs in the peripheral blood could possibly help in the understanding of the patients' reaction to a disease.

The isolation procedure of ovine PB-MSCs (oPB-MSCs) would facilitate the sampling of these progenitor cells for use in a wide variety of applications, including fundamental and applied studies of orthopaedics or prion diseases. Here, we present the first study describing the isolation and characterization of oPB-MSCs. The osteogenic, chondrogenic and adipogenic differentiation potential of oPB-MSCs was analysed *in vitro* and monitored by specific staining and molecular differentiation markers. We also demonstrate the capacity of these cells to differentiate into neuron-like cells and the expression of the gene coding for the prion protein (*PRNP*) in both regular and differentiated cells.

Results
=======

Isolation and characterization of peripheral blood derived fibroblast-like cells
--------------------------------------------------------------------------------

### Isolation and expansion of peripheral blood derived fibroblast-like cells

Plastic-adherent fibroblast-like cells were observed within the first days of culture of the nucleated cell fraction of peripheral blood obtained from total six sheep. Although the volume of blood collected was similar for all animals (approximately 25 mL), the number of peripheral blood nucleated cells (PBNC) obtained was variable, ranging from 0.594 10^6^ to 1.9 10^6^ PBNC/mL, with mean 1.36 10^6^ ± 682646. After the isolation process, a mean of 281400 ± 178051 adherent cells were obtained from each individual, varying between 2.7 and 9.3 adherent cells for every 1000 PBNC (mean: 5.85 ± 2.7).

Cells were expanded until the second passage and then frozen. The proliferation capacity of the adherent cells was measured during the first two passages. An average of 12.6 days was necessary to complete the first passage. Mean cell doubling during the first passage was 2.29 ± 0.887 and the doubling time was 5.99 ± 1.86 days. Time required to complete the second passage was shortened to 7.33 days, cell doubling decreased to 1.84 ± 0.975 and the doubling time was 4.88 ± 2.68 days.

After thawing, the cells from passage 2 were expanded for two more passages to obtain sufficient amount of cells for the differentiation assays. The cells were then characterized by analysing the expression of cell surface markers and the tri-lineage differentiation potential into adipocytes, osteoblasts and chondrocytes.

### Expression of mesenchymal cell surface markers

To initiate the characterization of oPB-MSCs, the expression of six cell surface markers specific for mesenchymal and haematopoietic cells were first analysed at the transcript level by quantitative real time PCR (RT-qPCR). All analysed cultures expressed *CD29* (integrin β1), *CD73* (ecto-5'-nucleotidase) and *CD90* (Thy-1), whereas the expression of *CD34* (CD34 molecule) was detected in five out of six of these cultures. The amplification of the hematopoietic marker *CD45* (protein tyrosine phosphatase, receptor type, C) was not detected and *CD105* (endoglin) was only weakly amplified at threshold cycles above 35.

### Adipogenic potential

Cells cultured under adipogenic conditions presented cytoplasmic lipid droplets under light microscope, although the size of the droplets was variable depending on the donor animal. To confirm that the contents of the droplets were lipids, the cultures were stained with oil red O (Figure [1](#F1){ref-type="fig"}A and B). The expression of adipogenic markers was analysed on days 7 and 14 of post-induction. The expression profiles of *PPARG* (peroxisome proliferator-activated receptor gamma), *SCD* (stearoyl-CoA desaturase) and *IL6* (interleukin 6) are shown in Figure [2](#F2){ref-type="fig"}. During the induction of differentiation, the *PPARG* and *SCD* mRNA expression levels increased to 7.3- and 20.8-fold, respectively. However, these changes were not statistically significant due to the high variability observed between animals. A significant downregulation of *IL6* (−31-fold, *P* \< 0.05) was detected after two weeks of culture (Figure [2](#F2){ref-type="fig"}A).

![**Staining for adipogenic, osteogenic and chondrogenic differentiation of PB-MSCs.** Oil red O staining of cells cultured for 15 days in basal (**A**) and adipogenic differentiation medium (**B**). Alizarin red staining of cells cultured for 21 days in basal (**C)** and osteogenic differentiation medium (**D**). Alcian blue staining of cells cultured for 21 days in basal (**E**) and chondrogenic medium (**F**).](1746-6148-8-169-1){#F1}

![**Quantitative real time PCR analysis.** Expression of the adipogenic (**A**), osteogenic (**B**) and chondrogenic (**C**) markers at different times of the differentiation process relative to the levels observed in control cultures (values set to 1, horizontal line)**.** Data are shown as mean ± standard errors. Statistically significant differences between differentiated and control cells were determined by Student t test (\**P* \< 0.05).](1746-6148-8-169-2){#F2}

### Osteogenic potential

The ability of oPB-MSCs to differentiate into osteoblasts was demonstrated using alizarin red staining (Figure [1](#F1){ref-type="fig"}C and D). Nodule-like aggregations stained in red appeared in the osteogenic media on the 21^st^ day of culture exclusively, indicating that these cultures were mineralized at a relatively late stage. However, the cells from different animals displayed variable osteogenic potential. The expression of osteogenic markers was evaluated in the cultures that displayed positive staining (n = 2). The expression levels of *COL1A1* (collagen, type 1, α 1) were not altered during the first 2 weeks in osteogenic media. However, a strong downregulation of *COL1A1* was observed at 3 weeks of culture. In contrast, the expression levels of *BGLAP* (bone gamma-carboxyglutamate (gla) protein, or osteocalcin) increased drastically throughout the culture period (Figure [2](#F2){ref-type="fig"}B).

### Chondrogenic potential

The chondrogenic potential was evaluated in monolayer cultures. Ovine PB-MSCs formed nodule-like aggregations in both control and induced conditions. However, the oPB-MSCs in chondrogenic media displayed a stronger staining with alcian blue (Figure [1](#F1){ref-type="fig"}F). Although the chondrogenic marker expression analysis did not reveal variations in the gene expression levels of the *BGN* (biglycan), *LUM* (lumican) was found to be upregulated on the 21^st^ day of culture (Figure [2](#F2){ref-type="fig"}C).

Neuronal differentiation of oPB-MSCs
------------------------------------

The ability of the isolated cells to transdifferentiate into neuronal cells was evaluated *in vitro*. The cells cultured under neurogenic conditions displayed distinctly altered morphology after the first 24 hours of induction. Differentiated cells were sharply defined, retracted towards the nucleus displaying phase-bright bodies, and some neurite-like processes (thin, long, and often branched) became apparent (Figure [3](#F3){ref-type="fig"}B,C). Neuronal differentiation was also demonstrated using RT-qPCR analysis. Control cells displayed none or very low levels of *NELF* (nasal embryonic LHRH factor) expression on 3 and 6 days of culture, while low expression levels of the remaining markers (*MAP2* \[microtubule-associated protein 2\], *NES* \[nestin\], *NEFM* \[neurofilament, medium polypeptide\], *TUBB3* \[tubulin, beta 3\]) were observed. The expression of these markers increased in neurogenic conditions, with a peak of expression on day 6 post-induction. Statistically significant changes were found for *NELF* on day 3 of culture (5.85 fold induction, *P* \< 0.001) and an over-expression tendency was observed for *MAP2* on day 6 (2.4 fold induction, *P* \< 0.1). Moreover, oPB-MSCs expressed transcripts of the prion protein (*PRNP*), which increased up to 5 times during the neurogenic period (Figure [3](#F3){ref-type="fig"}D).

![**Neurogenic differentiation of PB-MSCs.** Phase contrast micrograph of ovine PB-MSCs at passage 3 cultured on basal and neurogenic medium for 3 days. Control cells (**A**) showed a fibroblast-like shape whereas differentiated cells (**B**) displayed neuronal-like features such as phase-bright bodies, long multipolar extensions and branching ends (**C**: higher magnification). Increase of the expression levels of neurogenic markers after 3 (white bars) and 6 (grey bars) days of induction relative to the levels observed in cells cultured on basal medium (values set to 1, horizontal line) as assessed by real time PCR. Data are shown as mean ± standard errors. Statistically significant differences between differentiated and control cells were determined by Student t test (▪ *P* \< 0.10, \*\*\* *P* \< 0.001).](1746-6148-8-169-3){#F3}

Discussion
==========

Despite the importance of ovine as a large animal model for many conditions (i.e., orthopaedic injuries or Transmissible Spongiform Encephalopathies) the characterisation of ovine MSCs (oMSCs) is still limited. During the last decade, there has been an important effort within the scientific community to focus on the characterisation of MSCs obtained from different species, including the sheep. However, most research on MSCs has been performed on cells derived from bone marrow and, to a lesser degree, adipose tissue. The osteogenic and chondrogenic differentiation potential of MSCs *in vitro*\[[@B20]-[@B22]\] and *in vivo*\[[@B23],[@B24]\] is currently relatively well understood. Their phenotype for mesenchymal surface cell markers has also been analysed \[[@B25]\], and their proliferative potential has been shown to be heterogeneous \[[@B26]\]. Although the existence of MSCs in peripheral blood has been demonstrated in many species \[[@B17],[@B18]\], this work represents the first report describing the isolation of these cells from sheep circulation.

The minimal criteria to define human MSCs proposed by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy are: (1) plastic-adhesion when maintained in standard culture conditions; (2) expression of CD105, CD73 and CD90, and lack expression of the haematopoietic markers CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules and; (3) ability to differentiate to osteoblasts, adipocytes and chondroblasts *in vitro*\[[@B27]\]. In our study, plastic-adherent cells with a fibroblast-like morphology were obtained from all experimental sheep and were further analysed to determine the expression of mesenchymal markers and their ability to differentiate into adipocytes, osteoblasts and chondrocytes.

In other domestic species \[[@B28]\] the proportion of MSCs in the peripheral blood is low, which is in agreement with the few colonies of MSCs detected in our original oPB-MSCs cultures. Although the proliferation ability of oPB-MSCs was very different between individuals, the doubling time was generally longer than in other species, such as horse \[[@B29]\]. This difference may be due to the higher percentage of FBS used in the isolation of equine PB-MSCs (30%) and also due to the addition of dexamethasone to the growth media, which has been demonstrated to favour the expansion of MSCs \[[@B30]\]. The variability observed in this work is in accordance with the high heterogeneity in the proliferative potential of oMSCs obtained from bone marrow (oBM-MSCs) \[[@B26]\].

The absence of a well-defined immunophenotype for PB-MSCs renders the comparison of studies difficult. Moreover, most of the cell surface markers utilized to sort subpopulations of human MSC by flow cytometry have not been validated in sheep \[[@B21]\]. Gene expression-based technologies may be useful for the identification of possible molecules described as MSC markers \[[@B31],[@B32]\]. In our study, RT-qPCR was performed to quantify the mRNA expression levels of six cell surface antigens considered as either positive (*CD29*, *CD73*, *CD90* and *CD105*) or negative (*CD34* and *CD45*) MSC markers in humans.

In accordance with the immunophenotype described for human PB-MSCs \[[@B33]-[@B35]\], our expression analysis revealed significant amplification of the typical MSC markers, *CD29*, *CD73* and *CD90*, and a weak signal for *CD105*. In contrast, the haematopoietic marker *CD45* was not expressed. To our knowledge, there are no published data concerning the gene expression of cell surface markers in oMSCs obtained from other tissues. However, we have observed amplification of *CD29*, *CD73* and *CD90* in oBM-MSCs, as well as the lack of *CD34* and *CD45* expression (unpublished work from our group). Using flow cytometry, the presence of CD29 and CD105 has also been detected in oBM-MSCs \[[@B21],[@B36]\]. Additionally, oMSCs isolated from adipose tissue (oAT-MSCs) display high expression of CD90 and low immunoreactivity for CD105 \[[@B25]\]. The immunophenotypes of oBM-MSCs \[[@B36]\] and oAT-MSCs \[[@B25]\] are negative for the haematopoietic CD34 marker. However, this marker is expressed at low levels in human PB-MSCs \[[@B37]\] and in equine MSCs derived from adipose tissue \[[@B38]\] as demonstrated by RT-qPCR. We detected *CD34* expression in 5 out of 6 cultures, which may indicate individual variability. Finally, the cells analysed were negative for the haematopoietic marker *CD45*, as are human MSCs \[[@B16]\]. We have previously found a good correlation between MSC marker gene expression and the immunophenotype detected by flow cytometry in equine MSCs \[[@B39]\]. Although flow cytometry analysis is necessary to validate the immunophenotype of the isolated cells, the gene expression profile observed in this work strongly suggests that the peripheral blood derived fibroblast-like cells obtained as described would fulfill the requirements to be considered as MSCs.

Ovine BM-MSCs can be differentiated into adipocytes, showing lipid droplets in their cytoplasm and the induction of adipogenic markers \[[@B20],[@B36]\]. Similarly, adipogenic differentiation has been achieved here in all peripheral blood derived cell cultures, although great variability in the size of lipid droplets was observed. The expression of two adipogenic markers was evaluated in the cultures using RT-qPCR. PPARG is considered the master regulator of adipogenesis \[[@B40],[@B41]\] and is up-regulated in MSCs under adipogenic conditions \[[@B42]\]. SCD is expressed uniquely in adipocytes and catalyzes the rate-limiting step in the synthesis of poly-unsaturated fatty acids, thereby exhibiting a pivotal role in adipocyte metabolism \[[@B43]\]. Inter-individual variability was also noticeable in the expression of these adipogenic markers, which explains the lack of statistically significant differences in *PPARG* and *SCD* expression results despite the strong overexpression observed throughout the culture period. We also determined the expression of IL-6, which maintains the proliferative and undifferentiated state of bone marrow-derived MSCs \[[@B44]\] and is down-regulated during lineage-specific differentiation \[[@B45]\]. In accordance with these reports, a significant decrease was detected in the expression of *IL6* in the differentiated cultures. Therefore, using specific staining and gene expression profiles of adipogenic markers, we have confirmed the adipogenic potential of oPB-MSCs.

Similar to the adipogenic analysis, a great individual variation was also observed in the osteogenic potential. Osteogenic mineralization was confirmed on the last day of culture in osteogenic conditions (21 days) by staining calcium deposits with alizarin red. The induction period necessary for visualization of matrix mineralisation in oMSCs varies among different studies. The period reported for oBM-MSC mineralisation ranges from 21 days \[[@B36]\] to 5 weeks \[[@B21]\], while 4 weeks are required to differentiate periodontal oMSCs \[[@B46]\]. The weak alizarin red staining observed in some of our experiments could be due to the relatively short period of induction.

Although COL1A1 is considered an early marker of osteoprogenitor cells \[[@B47]\], we observed either no changes or a strong down-regulation on the 21st day of culture. Besides displaying a rapid mineralisation, oBM-MSCs cultured under osteogenic conditions express increased or declined levels of COL1A1 depending on the differentiation moment \[[@B21]\]. Other authors have reported either no significant increase in *COL1A1* mRNA expression levels after osteogenic differentiation in human \[[@B48]\], porcine \[[@B49]\] and equine \[[@B39]\] MSCs, or a down-regulation of this marker in human PB-MSCs during osteogenesis \[[@B50]\]. Therefore, *COL1A1* may not be suitable for monitoring osteogenesis in oPB-MSCs. In contrast, *BGLAP* was upregulated during the differentiation process and was maximally expressed on the last day of culture (day 21), coinciding with the positive alizarin red staining. This is in accordance with the role of BGLAP as a late marker of developing osteoblasts \[[@B51]\].

The sheep has been used as a large animal model for the studies of chondrogenesis both *in vivo*\[[@B52]\] and *in vitro*\[[@B22]\]. The chondrogenic potential of oMSCs has been evaluated mainly in micromass cultures of cells derived from bone marrow \[[@B20],[@B21],[@B36]\]. Chondrogenesis was evaluated in our study using a bidimensional culture with a high cell concentration seeding, according to the protocol described by Jäger et al. \[[@B53]\] for chondrogenic differentiation of ovine umbilical cord blood-derived MSCs. Chondrogenic nodules were observed in both control and chondrogenic media, although the staining was stronger in the induced cultures. The confirmation with molecular markers was not straightforward as the expression of the two components of the extracellular matrix *BGN* and *LUM* changed in opposite directions during chondrogenic differentiation. In accordance to our results, the lack of strong *BGN* overexpression has been reported for chondrogenic induced micropellets of oBM-MSCs \[[@B36]\]. However, further analysis is necessary to fully confirm the ability of oPB-MSCs to differentiate into chondrocytes.

During the last decade, many reports have described the *in vitro* neural transdifferentiation of MSCs derived from a range of species \[[@B2],[@B54],[@B55]\] but, to our knowledge, this has never been investigated in oMSCs. Neurogenic capacity of PB-MSCs would offer exciting possibilities for autologous therapeutic treatments for a variety of neurological disorders. As ovine is a natural model for prion diseases, the transdifferentiation of MSCs into neural cells could provide an excellent *in vitro* model for the study of these pathologies. Here, we described alterations in the morphology and expression profiles of neurogenic markers (*MAP2, NEFM, NELF, NES* and *TUBB3*) that are consistent with neural differentiation. In addition, we detected up-regulation of *PRNP*, which could also be involved in the morphological changes as the cellular prion protein seems to be necessary for neuritogenesis \[[@B56]\]. The variable success in the ability to transdifferentiate MSCs to a neural phenotype could be influenced by the inter-donor variability of expression of neural-related markers in MSCs prior to differentiation \[[@B57]\]. Nevertheless, our study shows that oPB-MSCs retain the ability to transdifferentiate. Finally, although murine bone marrow stromal cells express the prion protein \[[@B58]\], this has not been previously shown in species susceptible to prion diseases. In the present work, we have demonstrated the expression of *PRNP* in oPB-MSCs and its overexpression during neuronal differentiation.

Conclusions
===========

In this study we describe, for the first time, the isolation of mesenchymal stem cells from ovine peripheral blood. These cells express mesenchymal markers and retain the ability to differentiate into adipocytes and osteoblasts. Although oPB-MSCs seem to differentiate into chondrocytes, further studies are necessary to confirm the suitability of these cells for chondrogenesis studies. Finally, these cells can transdifferentiate into neuron-like cells and express *PRNP*.

Methods
=======

Animals and MSC isolation
-------------------------

Peripheral blood (25 mL) was obtained from a total of 6 sheep aged 1.5 to 6 years. The animals belonged to the Rasa Aragonesa breed and came from regional flocks. The procedure for blood collection from commercial farm animals was performed according to the recommendations of the Joint Working Group on Refinement \[[@B59]\]. The ethics committee of the University of Zaragoza approved the study (PI38/10). The blood was collected in 5 mL tubes with sodium heparin. Immediately after, blood was diluted in 1 volume of PBS and layered over Lymphoprep (Atom) in a 1:1 proportion. The mononuclear fraction was harvested after a density gradient centrifugation step of 20 min at 1600 g. Mononuclear cells were rinsed twice in the same volume of PBS by centrifugation for 5 min at 1600 g. The cells were resuspended, counted and plated at 10^6^ cells/cm^2^ in 6-well plates with basal medium consisting of low glucose Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 20% foetal bovine serum (FBS), 1% L-glutamine (Sigma-Aldrich) and 1% streptomycin/penicillin (Sigma-Aldrich).

Non-adherent cells were removed washing the mononuclear cells twice with PBS after 24, 48 and 72 h of incubation at 37°C and 5% CO~2~ and were maintained in growth medium until reaching approximately 80% confluence. The cells were then treated with trypsin (Sigma Aldrich) and plated either in T75 or T175 flasks (Becton Dickinson) at 5000 cells/cm^2^ in basal medium with 10% FBS. The cells were trypsinised until the second passage (P2) and then cryopreserved in FBS with 10% DMSO.

The yield of adherent cells during these two passages was used to characterize the self renewal capacity of the cells isolated towards the estimation of the cell doubling (CD) and the doubling time (DT) parameters. These values were calculated using the formula: CD = ln (Nf/Ni)/ ln2; DT: time (days)/ CD, Nf being the final number of cells in the culture, and Ni the initial number.

Approximately 10^6^ cells from passage two were thawed at 37°C and plated in a T75 flask. Cells were grown for two more passages prior to being used for the differentiation analyses.

Adipogenic differentiation
--------------------------

The cells obtained from the 6 sheep were seeded at 5000 cells/cm^2^ in 24-well plates with a previously described adipogenic medium \[[@B39]\]. Four replicates were seeded for each sheep, two were cultured with growth (control) medium and the other two with the adipogenic medium. The medium was changed every 3 days, and the differentiation was maintained for 14 days. To analyse the adipogenic differentiation, cells were fixed in 10% formalin (Sigma-Aldrich) for 15 min, and lipid droplets formed inside the cells were stained with 0.3% oil red O (Sigma-Aldrich). The expression of the adipogenic markers *PPARG*, *SCD* and *IL6* was analysed at days 7 and 14 of culture using RT-qPCR.

Osteogenic differentiation
--------------------------

Cells from the 6 sheep were plated at 2 x 10^4^ cells/cm^2^ in 24-well plates and cultured under osteogenic conditions (two replicates) or with growth medium (two replicates) for 21 days as previously described \[[@B39]\]. To assess their osteogenic potential, cells at days 7, 14 and 21 were fixed in 70% ethanol for 1 h and stained with 2% Alizarin Red S (Sigma Aldrich) for 10 min. The transcript expression of the osteogenic markers *COL1A1* and *BGLAP* was evaluated by RT-qPCR at days 7, 14 and 21 of culture.

Chondrogenic differentiation
----------------------------

For chondrogenic differentiation in monolayer cultures (n = 5), 10^5^ cells/cm^2^ were seeded in 24-well plates with the chondrogenic media described by Jäger et al. \[[@B53]\] (two replicates) or with growth medium (two replicates). The culture was maintained for 21 days with the media being changed twice per week. To determine chondrogenic differentiation, the cultures were stained with alcian blue dye (Sigma-Aldrich). Briefly, cells were washed with PBS, fixed with 70% ethanol for 1 h at room temperature, washed three times with distilled water, stained with alcian blue stain diluted in methanol at a 1:1 proportion and washed with water until the excess staining was removed. *BGN* and *LUM* transcripts were quantified at days 10 and 21 of chondrogenic induction using RT-qPCR.

Neuronal differentiation
------------------------

The neurogenic potential of the isolated cells was tested in two cell lines. The cells were seeded at 2500 cells/cm^2^ in 24-well plates with the neurogenic medium (Thermo Scientific) (two replicates) or under growth medium (two replicates) and maintained for 6 days, changing the media every 3 days. Differentiation was monitored by both light microscope and analysis of the mRNA expression levels of neurogenic markers (*MAP2*, *NELF*, *NES*, *NEFM* and *TUBB3*) and *PRNP* by RT-qPCR at days 3 and 6.

Real Time quantitative PCR
--------------------------

The potential of cultured cells to differentiate into adipocytes, osteoblasts, chondrocytes and nervous cells was monitored via analysis of the expression levels of differentiation markers (Table [1](#T1){ref-type="table"}) using RT-qPCR. The same methodology was used to evaluate the expression levels of cell surface markers for mesenchymal (*CD29*, *CD73*, *CD90* and *CD105*) and haematopoietic (*CD34* and *CD45*) stem cells in undifferentiated cells. The primers for RT-qPCR were designed using Primer Express 2.0 software (Applied Biosystems).

###### 

Cell surface, adipogenic, osteogenic, chondrogenic and neurogenic markers analysed by RT-qPCR

  **Genes**                    **Accession number**            **Primer sequences**            **Amplicon size (bp)**    
  ---------------------------- ------------------------------- ------------------------------- ------------------------- -----
  ***Cell Surface Markers***                                                                                             
  ***CD29***                   AF349461                        GTGCCCGAGCCTTCAATAAAG           CCCGATTTTCAACCTTGGTAATG    87
  ***CD34***                   AB021662                        TGGGCATCGAGGACATCTCT            GATCAAGATGGCCAGCAGGAT      107
  ***CD45***                   NM_001206523                    CCTGGACACCACCTCAAAGCT           TCCGTCCTGGGTTTTATCCTG      101
  ***CD73***                   BC114093                        TGGTCCAGGCCTATGCTTTTG           GGGATGCTGCTGTTGAGAAGAA     115
  ***CD90***                   BC104530                        CAGAATACAGCTCCCGAACCAA          CACGTGTAGATCCCCTCATCCTT    96
  ***CD105***                  NM_001076397                    CGGACAGTGACCGTGAAGTTG           TGTTGTGGTTGGCCTCGATTA      115
                               ***Differentiation Markers***                                                                
  ***PPARG***                  NM_001100921                    GCCCTGGCAAAGCATTTGTA            TGTCTGTCGTCTTTCCCGTCA      94
  ***SCD***^***1***^           AJ001048                        CCCAGCTGTCAGAGAAAAGG            GATGAAGCACAACAGCAGGA       115
  ***IL6***                    FJ409227.1                      CAGCAAGGAGACACTGGCAG            TGATCAAGCAAATCGCCTGAT      101
  ***COL1A1***                 AF129287                        CCTGCGTACAGAACGGCCT             ACAGCACGTTGCCGTTGTC        93
  ***BGLAP***                  DQ418490                        CCCAGGAGGGAGGTGTGTG             CTAGACCGGGCCGTAGAAGC       99
  ***BGN***                    NM_001009201.1                  AACATGAACTGCATTGAGATGGG         GCGAAGGTAGTTGAGCTTCAGG     93
  ***LUM***                    NM_173934.1                     AAGCAATTGAAGAAGCTGCACA          TTAGTGAGCTGCAGGTCCACC      92
  ***NES***                    194665083                       CAAATCGCCCAGGTCCTG              GCCTCTAGGAGGGTCCTGTATGT    95
  ***NEFM***                   194669578                       GCTCGTCATCTGCGAGAATACC          CACCCTCCAGGAGTTTCCTGTA     91
  ***NELF***                   27806522                        CGCTATGCAGGACACAATCAAC          GGGTCTCCTCACCTTCCAAGA      161
  ***TUBB3***                  116004470                       GACCTCGAGCCTGGAACCAT            GCCCCACTCTGACCAAAGATG      92
  ***MAP2***                   194664873                       TGTCCCAGTGGAGGAAGGTTT           TCTTGTCTAGTGGCTCGGCTG      95
  ***PRNP***                   BC119821                        CGCAGAAGCAGGACTTCTGAA           TGGATTTGTGTCTCTGGGAAGA     86
  ***Housekeeping genes***                                                                                               
  ***G6PDH***^***2***^         AJ507200                        TGACCTATGGCAACCGATACAA          CCGCAAAAGACATCCAGGAT       76
  ***HPRT***^***3***^          EF078978                        AGGTGTTTATTCCTCATGGAGTAATTATG   GGCCTCCCATCTCCTTCATC       79

GenBank accession numbers of the sequences used for primer design. Primer sequences (F: Forward and R: Reverse) and the length of the amplicon in base pairs (bp).

^1^ Primers described in Dervishi et al. \[[@B60]\].

^2^ Primers described in García-Crespo et al. 2005 \[[@B61]\].

^3^ Primers described in Lyahyai et al. 2010 \[[@B62]\].

RNA extraction and cDNA synthesis were performed on both differentiated and control oPB-MSC cultures using the cells-to-cDNA kit (Ambion). The isolated cDNA was diluted 1:5 in water for further analysis. Amplification experiments were performed in triplicate using Fast SYBR Green Master Mix reagent (Life Technologies) and the StepOne™ Real Time System (Life Technologies). The levels of gene expression were determined using the comparative Ct method. A normalization factor (NF) calculated as the geometric mean of the quantity of two housekeeping genes (*GAPDH* and *HPRT*) was used to normalize the expression levels for each gene. Variations in gene expression between differentiated and control oPB-MSCs were evaluated with the Student's *t* test. Statistical significance was defined as *P* \< 0.05.
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